Well-authenticated biomarkers can provide critical insights into the biological basis of
Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and …

Background Mitochondrial electron transport chain abnormalities have been reported in
postmortem pathological specimens of Alzheimer’s disease (AD). However, it remains unclear …

Background Blood-based biomarkers of Alzheimer's disease (AD) have become increasingly
important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 …

Background and purpose Abnormal mitochondrial metabolism has been described in the
Alzheimer's disease (AD) brain. However, the relationship between AD pathophysiology and …

Background Risk factors for dementia have distinct frequency and impact in relation to race.
Our aim was to identify differences in modifiable risk factors of dementia related to races and …

Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity not yet
understood, that is present with transient neurologic symptoms and particular radiological …

Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiologic entity characterized
by headaches, altered mental status, seizures, visual loss, and characteristic imaging …

The frontal variant of Alzheimer disease (fvAD) is characterized by behavioral and/or
dysexecutive impairments that can resemble those of behavioral-variant frontotemporal dementia (…

Biomarkers are characteristics that are objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes or pharmacological responses to a …

Associations between pathophysiological events and cognitive measures provide insights
regarding brain networks affected during the clinical progression of Alzheimer’s disease (AD). …